Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

PRIMARY OBJECTIVES: I. To determine whether a K\^trans rise from nadir is predictive of subsequent tumor growth. SECONDARY OBJECTIVES: I. To determine the association between changes in mean ambulatory blood pressure measurements, K\^trans, and tumor size changes with pazopanib therapy. II. To determine the association between changes in soluble vascular endothelial growth factor receptor 2 (sVEGFR2) measurements, K\^trans, and tumor size changes with pazopanib therapy. TERTIARY OBJECTIVES: I. To explore previously described single nucleotide polymorphisms (SNP's) as pharmacogenomic biomarkers. II. To model tumor growth kinetics using radiologic tumor size measurements. III. To explore other serum and plasma based putative biomarkers of vascular endothelial growth factor (VEGF) pathway inhibition. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7. After completion of study treatment, patients are followed up every 3 months for 2 years.